Blueprint Medicines Corp (BPMC) Receives $87.11 Average Price Target from Analysts

Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $87.11.

A number of analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, February 21st. BidaskClub raised Blueprint Medicines from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Zacks Investment Research cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Friday, February 23rd. ValuEngine raised Blueprint Medicines from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, JMP Securities set a $109.00 target price on Blueprint Medicines and gave the stock a “buy” rating in a research note on Monday, April 16th.

Shares of BPMC stock traded up $0.11 on Monday, reaching $73.60. The company had a trading volume of 4,912 shares, compared to its average volume of 428,373. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.40 and a quick ratio of 15.40. The stock has a market cap of $3.08 billion, a PE ratio of -18.59 and a beta of 1.02. Blueprint Medicines has a 12 month low of $36.94 and a 12 month high of $109.00.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.23). The company had revenue of $0.95 million during the quarter, compared to the consensus estimate of $2.82 million. Blueprint Medicines had a negative net margin of 1,068.27% and a negative return on equity of 37.00%. The business’s revenue was down 83.7% compared to the same quarter last year. During the same period last year, the company earned ($0.84) earnings per share. research analysts anticipate that Blueprint Medicines will post -5.39 earnings per share for the current year.

In other Blueprint Medicines news, Director George Demetri sold 5,492 shares of the company’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $100.09, for a total transaction of $549,694.28. Following the completion of the transaction, the director now owns 10,231 shares of the company’s stock, valued at approximately $1,024,020.79. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $78.90, for a total value of $1,578,000.00. Following the transaction, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,578,000. The disclosure for this sale can be found here. Corporate insiders own 3.15% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 680 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Blueprint Medicines by 16.9% in the 4th quarter. Amalgamated Bank now owns 5,777 shares of the biotechnology company’s stock valued at $436,000 after buying an additional 837 shares during the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Blueprint Medicines by 1.0% in the 4th quarter. UBS Asset Management Americas Inc. now owns 109,788 shares of the biotechnology company’s stock valued at $8,279,000 after buying an additional 1,125 shares during the last quarter. Xact Kapitalforvaltning AB boosted its holdings in shares of Blueprint Medicines by 39.0% in the 1st quarter. Xact Kapitalforvaltning AB now owns 5,351 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 1,500 shares during the last quarter. Finally, Strs Ohio boosted its holdings in shares of Blueprint Medicines by 69.6% in the 4th quarter. Strs Ohio now owns 3,900 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 1,600 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply